MyFinsight
Home
Blog
About
Proceeds from issuance of
notes payable, net of...
$7,034,102
Proceeds from sale of
preferred stock, net of...
$2,288,025
Proceeds from sale of
common stock, net of...
$842,704
(-71.57%↓ Y/Y)
Net cash (used in)
provided by financing...
$10,163,031
(106.09%↑ Y/Y)
Canceled cashflow
$1,800
Net change in cash,
cash equivalents and...
$3,083,319
(369.52%↑ Y/Y)
Canceled cashflow
$7,079,712
Exercise of pre-funded
warrants, net
$1,800
Stock-based compensation
$641,871
(96.19%↑ Y/Y)
Common stock issued in
exchange for...
$455,351
Amortization of right-of-use
assets
$195,542
(-11.48%↓ Y/Y)
Depreciation
$140,000
(-1.19%↓ Y/Y)
Advances, deposits, and
other current assets
-$115,860
(-540.92%↓ Y/Y)
Ammortization of debt discount
and issuance costs
$35,410
Pik interest
accretion a-1 note
$16,096
Ammortization of debt issuance
costs b-note
$6,983
Net cash used in
operating activities
-$7,010,632
(-20.91%↓ Y/Y)
Net cash used in
investing activities
-$69,080
(75.06%↑ Y/Y)
Canceled cashflow
$1,607,113
Net loss
-$7,063,136
(-3.22%↓ Y/Y)
Purchases of property and
equipment
$69,080
(-75.06%↓ Y/Y)
Accounts payable and
accrued liabilities
-$1,532,422
(-502.09%↓ Y/Y)
Change in fair value of
derivative liability
$22,187
Back
Back
Cash Flow
Imunon, Inc. (IMNN)
Imunon, Inc. (IMNN)
source: myfinsight.com